New Haven, CTNCT07362888Now EnrollingIRB Ready

Solid Tumors (Phase 1) Clinical Trial in New Haven, CT

Access cutting-edge solid tumors (phase 1) treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Adcendo ApS

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access solid tumors (phase 1) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumors (phase 1) treatment provided free

Apply for This New Haven Location

Check if you qualify for this solid tumors (phase 1) clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Solid Tumors (Phase 1) Study in New Haven

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Sponsor: Adcendo ApS

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed diagnosis of solid tumor
Advanced disease (i.e., unresectable locally advanced or metastatic) and refractory to, intolerant of, or ineligible for approved therapies
Radiologically or clinically determined progressive disease during or after most recent line of therapy
Measurable disease per RECIST 1.1
ECOG performance status of 0 or 1
Adequate hematological and biochemical parameters
A male patient must agree to use barrier contraception during the treatment period and for at least 4 months after the last infusion of study treatment, and refrain from donating sperm during this period. Male patients with a pregnant partner must practice sexual abstinence or use a barrier method of contraception (e.g., condom) to prevent exposure of the fetus or neonate
A female patient who is not pregnant, not breast feeding, and either not a woman of childbearing potential (WOCBP) or agrees to follow the contraceptive guidance during the treatment period and for at least 7 months after last infusion of study treatment

Exclusion Criteria

Treatment with systemic anticancer therapy, including any investigational agent within 3 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration
Prior treatment with an ADC containing a topoisomerase I inhibitor payload
Primary brain malignancy or known, untreated central nervous system (CNS) or leptomeningeal metastases, or symptoms suggesting CNS involvement for which treatment is required
Other malignancy
Major surgical procedure or significant traumatic injury within 28 days prior to study drug administration
Ongoing systemic infection requiring treatment with antibiotics, antivirals, or antimycotics, other than prophylactic treatment
Persistent toxicities from previous systemic anti-neoplastic treatments of Grade \>1
Clinically significant cardiovascular disease
Acute infection with human immunodeficiency virus (HIV)-1 or HIV-2
Current active liver disease due to hepatitis B or hepatitis C
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis or pulmonary lymphangitic carcinomatosis

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT07362888) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumors (Phase 1) Treatment Options in New Haven, CT

If you're searching for solid tumors (phase 1) treatment options in New Haven, CT, this clinical trial (NCT07362888) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors (phase 1) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumors (phase 1) clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in New Haven, CT

See all advanced solid tumors clinical trials recruiting in New Haven — not just this study.

Browse Advanced Solid Tumors Trials in New Haven →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT